CoChat
Sign Up
Cited by 296Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Inflammatory dysregulation of blood monocytes in Parkinson’s disease patients

Open access
Grozdanov, Veselin, Bliederhaeuser, Corinna, Ruf, Wolfgang P., Roth, Valerie, Fundel-Clemens, Kathrin, Zondler, Lisa, Brenner, David, Martin-Villalba, Ana, Hengerer, Bastian, Kassubek, Jan, Ludolph, Albert C., Weishaupt, Jochen H., Danzer, Karin M.·2014·Acta Neuropathologica
DOI 10.1007/s00401-014-1345-4PMC PMC4201759
Open this paper in CoChat — free accountOpen PDF

Abstract

Despite extensive effort on studying inflammatory processes in the CNS of Parkinson's disease (PD) patients, implications of peripheral monocytes are still poorly understood. Here, we set out to obtain a comprehensive picture of circulating myeloid cells in PD patients. We applied a human primary monocyte culture system and flow cytometry-based techniques to determine the state of monocytes from PD patients during disease. We found that the classical monocytes are enriched in the blood of PD patients along with an increase in the monocyte-recruiting chemoattractant protein CCL2. Moreover, we found that monocytes from PD patients display a pathological hyperactivity in response to LPS stimulation that correlates with disease severity. Inflammatory pre-conditioning was also reflected on the transcriptome in PD monocytes using next-generation sequencing. Further, we identified the CD95/CD95L as a key regulator for the PD-associated alteration of circulating monocytes. Pharmacological neutralization of CD95L reverses the dysregulation of monocytic subpopulations in favor of non-classical monocytes. Our results suggest that PD monocytes are in an inflammatory predisposition responding with hyperactivation to a "second hit". These results provide the first direct evidence that circulating human peripheral blood monocytes are altered in terms of their function and composition in PD patients. This study provides insights into monocyte biology in PD and establishes a basis for future studies on peripheral inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-014-1345-4

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Classical (CD14+CD16−) monocytes are enriched in PD patients. a Representative FACS analysis of monocyte subpopulations from peripheral blood. Monocytes are gated out of other immune cells (FITC—CD2/CD15/CD19/CD335) by HLA-DR staining (PE-Cy7) and monocyte subpopulations characterized based on CD14 (PerCP-Cy5.5) and CD16 (PE) staining. b Total number of monocytes in peripheral blood as a percentage of total leukocytes. No significant difference between PD patients’ and healthy controls’ blood was found (Healthy controls n = 21, PD n = 14). c CD14+CD16− (classical) monocytes are enriched and CD14−/+CD16+ monocytes are decreased in the blood of PD patients. (Healthy controls n = 21, PD patients n = 14). Bars mean ± SEM, ****p < 0.0001
Fig. 1 Classical (CD14+CD16−) monocytes are enriched in PD patients. a Representative FACS analysis of monocyte subpopulations from peripheral blood. Monocytes are gated out of other immune cells (FITC—CD2/CD15/CD19/CD335) by HLA-DR staining (PE-Cy7) and monocyte subpopulations characterized based on CD14 (PerCP-Cy5.5) and CD16 (PE) staining. b Total number of monocytes in peripheral blood as a percentage of total leukocytes. No significant difference between PD patients’ and healthy controls’ blood was found (Healthy controls n = 21, PD n = 14). c CD14+CD16− (classical) monocytes are enriched and CD14−/+CD16+ monocytes are decreased in the blood of PD patients. (Healthy controls n = 21, PD patients n = 14). Bars mean ± SEM, ****p < 0.0001CC BY · PubMed Central
Fig. 2 Transcriptome-wide analysis of gene expression in PD and healthy control monocytes by next-generation sequencing reveals a distinct expression signature in PD monocytes. a Heatmap of 8,862 genes expressed over the threshold (FPKM >5). b Unsupervised hierarchical clustering based on the expression of 8,862 genes in blood monocytes successfully identified most PD cases and clustered them away from healthy controls. Clustering by complete linkage and cosine correlation. c Differential expression of selected top genes in PD monocytes. d Fold change of expression in PD monocytes vs. healthy controls’ monocytes. e Validation of selected genes’ expression in an independent cohort (healthy controls n = 13, PD patients n = 14) by qRT-PCR. Bars represent mean ± SEM, *p < 0.05, **p < 0.01, ****p < 0.0001
Fig. 2 Transcriptome-wide analysis of gene expression in PD and healthy control monocytes by next-generation sequencing reveals a distinct expression signature in PD monocytes. a Heatmap of 8,862 genes expressed over the threshold (FPKM >5). b Unsupervised hierarchical clustering based on the expression of 8,862 genes in blood monocytes successfully identified most PD cases and clustered them away from healthy controls. Clustering by complete linkage and cosine correlation. c Differential expression of selected top genes in PD monocytes. d Fold change of expression in PD monocytes vs. healthy controls’ monocytes. e Validation of selected genes’ expression in an independent cohort (healthy controls n = 13, PD patients n = 14) by qRT-PCR. Bars represent mean ± SEM, *p < 0.05, **p < 0.01, ****p < 0.0001CC BY · PubMed Central
Fig. 3 PD monocytes are hyperactive upon LPS stimulation. Monocytes from PD patients secrete significantly higher levels of IL-1β, IL-6, IL-8 and IFNγ when stimulated with 1 ng/ml LPS compared to monocytes from age-matched healthy controls (a–d). No significant difference in cytokine secretion was observed for TNFα (p = 0.05), and IL-10 (p = 0.52) (e, f). Bars represent mean ± SEM. PD patients (n = 10), healthy controls (n = 10), *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. g Fold increase in cytokine production of monocytes from PD patients vs. healthy controls. h Correlation between IL-6 release after 24 h stimulation with 1 ng/ml LPS and PD severity staged with the H&Y scale. Dotted lines indicate the 95 % CI of the linear regression. r Spearman’s correlation coefficient. i Decreased phagocytic function of Parkinson’s disease monocytes, healthy controls (n = 15), PD patients (n = 11). Bars represent mean ± SEM, *p < 0.05
Fig. 3 PD monocytes are hyperactive upon LPS stimulation. Monocytes from PD patients secrete significantly higher levels of IL-1β, IL-6, IL-8 and IFNγ when stimulated with 1 ng/ml LPS compared to monocytes from age-matched healthy controls (a–d). No significant difference in cytokine secretion was observed for TNFα (p = 0.05), and IL-10 (p = 0.52) (e, f). Bars represent mean ± SEM. PD patients (n = 10), healthy controls (n = 10), *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. g Fold increase in cytokine production of monocytes from PD patients vs. healthy controls. h Correlation between IL-6 release after 24 h stimulation with 1 ng/ml LPS and PD severity staged with the H&Y scale. Dotted lines indicate the 95 % CI of the linear regression. r Spearman’s correlation coefficient. i Decreased phagocytic function of Parkinson’s disease monocytes, healthy controls (n = 15), PD patients (n = 11). Bars represent mean ± SEM, *p < 0.05CC BY · PubMed Central
Fig. 4 The CCR2–CCL2 axis is activated in PD. a Monocytes from PD patients release significantly higher levels of CCL2 upon LPS stimulation (LPS 1 ng/ml, healthy controls n = 10, Parkinson’s disease patients n = 10, *p < 0.05). b CCL2 is significantly increased (*p < 0.05) in the serum of PD patients (n = 53) when compared to healthy controls (n = 34). Bars represent mean ± SEM
Fig. 4 The CCR2–CCL2 axis is activated in PD. a Monocytes from PD patients release significantly higher levels of CCL2 upon LPS stimulation (LPS 1 ng/ml, healthy controls n = 10, Parkinson’s disease patients n = 10, *p < 0.05). b CCL2 is significantly increased (*p < 0.05) in the serum of PD patients (n = 53) when compared to healthy controls (n = 34). Bars represent mean ± SEMCC BY · PubMed Central
Fig. 5 FAS/FASLG upregulation in monocytes from PD patients. The expression of both FAS (a) and FASLG (b) is upregulated in unstimulated PD monocytes (Healthy controls n = 14, PD patients n = 14). c Monocytes are enriched in PD leukocyte cultures after 48 h treatment with FASLG-inhibitor APG101 (n = 15, APG 0.25 mg/ml). d Classical (CD14+CD16−) monocytes are decreased and non-classical (CD14−CD16+) monocytes are increased by treatment of PD leukocytes with APG101 in culture (n = 15). Bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 5 FAS/FASLG upregulation in monocytes from PD patients. The expression of both FAS (a) and FASLG (b) is upregulated in unstimulated PD monocytes (Healthy controls n = 14, PD patients n = 14). c Monocytes are enriched in PD leukocyte cultures after 48 h treatment with FASLG-inhibitor APG101 (n = 15, APG 0.25 mg/ml). d Classical (CD14+CD16−) monocytes are decreased and non-classical (CD14−CD16+) monocytes are increased by treatment of PD leukocytes with APG101 in culture (n = 15). Bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 296

Related

See all

Metadata

Authors
Grozdanov, V., Bliederhaeuser, C., Ruf, W. P., Roth, V., Fundel-Clemens, K., Zondler, L., Brenner, D., Martin-Villalba, A., Hengerer, B., Kassubek, J., Ludolph, A. C., Weishaupt, J. H., & Danzer, K. M.
Affiliations
  • Universität Ulm (DE)
  • Boehringer Ingelheim (Germany) (DE)
Corresponding author
Danzer, Karin M.
ORCID
Venue
Acta Neuropathologica
Publisher
Springer Science and Business Media LLC
Published
2014-10-05
Volume
128
Issue
5
Pages
651-663
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
DOI
10.1007/s00401-014-1345-4
PMC
PMC4201759
OpenAlex
W2003612310
Cited by
295
References
44
Citations by year
2026: 23 · 2025: 31 · 2024: 38 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 26 · 2019: 19 · 2018: 18 · 2017: 18 · 2016: 13 · 2015: 9
FWCI
8.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fondation Charcot
  • Universität Ulm
  • Medizinische Fakultät, Universität Ulm
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkinson's disease, peripheral blood monocytes, classical monocytes, MCP-1, lipopolysaccharide response, non-classical monocytes, peripheral inflammation, monocyte transcriptome, disease severity
MeSH terms
Cells, Cultured, Culture Media, Female, Flow Cytometry, Humans, Inflammation, Lipopolysaccharides, Male, Monocytes, Parkinson Disease, Phagocytosis, Psychiatric Status Rating Scales, RNA, Messenger, Cohort Studies, Antigens, CD, Interleukin-6, Cytokines, Chemokine CCL2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review